Novartis to sell animal health businessSwiss drugmaker Novartis is ready to sell its animal health subsidiary and has opened its books to Bayer and other rivals interested in a business that could change hands for more than 3 billion euros ($4.1 billion), sources familiar with the matter say.
By: Ludwig Burger and Arno Schuetze, Reuters
FRANKFURT — Swiss drugmaker Novartis is ready to sell its animal health subsidiary and has opened its books to Bayer and other rivals interested in a business that could change hands for more than 3 billion euros ($4.1 billion), sources familiar with the matter say.
Germany’s Bayer is seeking to bolster its position as a diversified life sciences company and made clear its interest in the animal health sector on Dec. 3, though it faces competition from at least two rivals.
Suitors including Bayer, Eli Lilly of the U.S. and Germany’s unlisted Boehringer are conducting due diligence assessments of the business, the financial sources say.
Novartis declined to comment on a possible sale, but Chief Executive Joe Jimenez and Chairman Joerg Reinhardt say they are considering options for noncore assets that lack the scale to become world leaders.
“Animal health has been a ‘grow or go’ topic for Novartis for some time. The new management has now decided to make the cut,” says one banker familiar with the matter.
Shortly after Reinhardt joined Novartis as chairman in August — from his previous job as Bayer’s head of health care — he suggested a review of some of the Swiss drugmaker’s underperforming businesses.
Bayer, in turn, is more focused on expansion. “We are interested in growing our animal health business,” CEO Marijn Dekkers said at a pharmaceuticals conference in London on Dec. 3, though he declined to comment on whether it is looking at the Novartis assets.
“For Bayer it would be a good fit in principle,” says M.M. Warburg & Co. analyst Ulrich Huwald. “It’s a business with strong cash flows, stable income and synergies with the development of human medicines.”
Eli Lilly was not immediately available for comment and Boehringer declined to comment.
Combining Bayer’s veterinary drug sales of about $1.7 billion with Novartis’s $1.1 billion would lift the German company from fifth place to third or fourth in the global animal health market, where former Pfizer subsidiary Zoetis leads the way.
Eli Lilly’s veterinary drugs business had $2 billion in sales last year, making it the No. 4 player, while Boehringer was sixth with $1.3 billion. Merck & Co. and Sanofi sit at No. 2 and No. 3 respectively, with sales of $3.4 billion and $2.8 billion.
Citi analyst Andrew Baum estimated in a note on Oct. 22 that Novartis’s animal health unit would be worth about $4 billion.
Bankers say the asset could be valued at about 15 to 16 times earnings before interest, tax, depreciation and amortization (EBITDA), but Novartis has not provided an EBITDA breakdown for animal health.
According to StarMine data, Zoetis’s market value including debt stands at 4.3 times current sales and 17.5 times EBITDA.
The animal health sector is expected to grow faster than the global economy as aging western societies spend more money on pets, while livestock farming increases in emerging markets, where appetite for meat rises with average household incomes.
The potential sale of Novartis’s animal health business would be part of the company’s continuing review of operations, which last month resulted in the sale of its blood transfusion testing unit to Spain’s Grifols for $1.68 billion.
The sources say that Novartis has hired Goldman Sachs to assist it in the review. Goldman declined to comment.